Trials / Withdrawn
WithdrawnNCT05647447
Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate
Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate (POSH-MAP)
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the preliminary efficacy of in reducing the frequency and severity of hot flashes in men on androgen deprivation therapy (ADT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Osanetant | Osanetant 200 mg orally, twice per day |
Timeline
- Start date
- 2023-01-03
- Primary completion
- 2023-09-22
- Completion
- 2023-10-05
- First posted
- 2022-12-12
- Last updated
- 2024-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05647447. Inclusion in this directory is not an endorsement.